Clinical outcomes and healthcare resource utilization associated with reslizumab treatment in adults with severe eosinophilic asthma in real-world practice.

Clinical outcomes and healthcare resource utilization associated with reslizumab treatment in adults with severe eosinophilic asthma in real-world practice. Chest. 2020 Dec 14;: Authors: Wechsler ME, Peters SP, Hill TD, Ariely R, DePietro MR, Driessen MT, Terasawa EL, Thomason DR, Panettieri RA Abstract BACKGROUND: Reslizumab, an anti-interleukin-5 (anti-IL-5) monoclonal antibody, is indicated as add-on maintenance treatment for adults with severe eosinophilic asthma. RESEARCH QUESTION: This retrospective study examined real-world outcomes associated with reslizumab use in patients with severe eosinophilic asthma in US clinical practice. STUDY DESIGN AND METHODS: Patient-level data from adults treated with reslizumab were obtained from center- and panel-based medical chart reviews. Eligible patients had available medical records and treatment history for ≥ 6 months pre-reslizumab treatment initiation (index date) to ≥ 7 months post-reslizumab initiation. The primary outcome was response to reslizumab treatment, based on clinical expert pre-defined definitions of response. Other outcomes included clinical asthma exacerbations (CAE), use of maintenance oral corticosteroids (OCS), forced expiratory volume in 1 second (FEV1) percent predicted, Asthma Control Test (ACT) score, and healthcare resource utilization (HRU). RESULTS: Medical charts were obtained for 215 patients. Most patients (58.6%) had excellent r...
Source: Chest - Category: Respiratory Medicine Authors: Tags: Chest Source Type: research